Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27201495 | 0.77 | IRAK4 (0.54) | IRAK4FLT3HDAC4PDGFRBMAPK8 | |
| SCHEMBL27201566 | 0.76 | IRAK4 (0.41) | IRAK4FLT3SSTR4 | |
| SCHEMBL5762778 | 0.76 | IRAK4 (0.50) | IRAK4FLT3HDAC4MAPK8NPSR1 | |
| Hydrochloric Acid SCHEMBL947525 | 0.75 | IRAK4 (0.49) | IRAK4FLT3HDAC4MAPK8NPSR1 | |
| Hydrochloric Acid SCHEMBL26911778 | 0.75 | IRAK4 (0.49) | IRAK4FLT3HDAC4MAPK8NPSR1 | |
| SCHEMBL27201545 | 0.74 | ADORA3 (0.43) | IRAK4FLT3HDAC4SSTR4MAPK8 | |
| SCHEMBL25521500 | 0.69 | IRAK4 (0.45) | IRAK4FLT3HDAC4KDRNPSR1 | |
| SCHEMBL20993216 | 0.65 | DDB1 (0.37) | — | |
| SCHEMBL20993362 | 0.65 | DDB1 (0.37) | — | |
| SCHEMBL987383 | 0.65 | DDB1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | IRAK4 1128/4885FLT3 3098/4885HDAC4 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.